The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Travel
  • Financial
  • Construction

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • Inkdnylon Expands National Uniform Embroidery Services
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
  • Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
  • Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
  • IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
  • Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Zac Arbitman Elected As Co-Chair of Philadelphia Bar Association Federal Courts Committee
  • CCHR Florida Joins Global Call to Ban Electroshock Treatment, Citing New Evidence of Widespread Patient Harm
  • BoxingRx Announces Full Gym Renovation Ahead of New Ownership's One-Year Anniversary
  • UK Financial Ltd Announces It's Official Corporate Headquarters In The United Kingdom
  • Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
  • Twin Flame Visions Announces Surge in Traffic and Engagement Following Breakout Ad Performance
  • FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
  • Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
  • "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
  • Megan Markovci Honored as One of Top Young Travel Agents in the Industry
  • DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • Accelerating Precious Metals Expansion and Digital Asset Innovation Ahead of 2026: Asia Broadband Inc. (Stock Symbol: AABB)
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
  • London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success
  • God's Meal Barrel Combats the Increased Community Need in 2025
  • myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
  • Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
  • Philadelphia Startup NoPlex Creates an ADHD/Neurodiversity-Focused Alternative to Productivity Apps

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 776
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 233
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 112
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • Discover Elevated Living - Preview the Stunning New Townhome Collection
  • Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
  • Free At Last Bail Bonds Gives Back Through Major Holiday Food Distribution Efforts Across Metro Atlanta
  • Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market

Similar on PennZone

  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
  • MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us